"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

A federal judge has shut down compounding pharmacies from making cheaper versions of Eli Lilly’s weight loss and diabetes ...